Equities analysts expect Sientra, Inc. (NASDAQ:SIEN) to announce sales of $17.90 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Sientra’s earnings, with estimates ranging from $17.50 million to $18.10 million. Sientra posted sales of $19.22 million in the same quarter last year, which would indicate a negative year over year growth rate of 6.9%. The business is expected to announce its next earnings results on Monday, November 8th.
According to Zacks, analysts expect that Sientra will report full year sales of $78.57 million for the current fiscal year, with estimates ranging from $76.50 million to $82.00 million. For the next fiscal year, analysts forecast that the firm will post sales of $96.50 million, with estimates ranging from $92.50 million to $99.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Sientra.
Sientra (NASDAQ:SIEN) last issued its earnings results on Tuesday, August 10th. The medical instruments supplier reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.13). Sientra had a negative return on equity of 901.29% and a negative net margin of 119.58%.
Shares of Sientra stock traded up $0.03 during trading on Tuesday, hitting $6.07. The stock had a trading volume of 430,695 shares, compared to its average volume of 896,049. The firm’s fifty day simple moving average is $7.02 and its 200-day simple moving average is $7.12. The stock has a market cap of $352.04 million, a PE ratio of -3.19 and a beta of 2.12. Sientra has a 12 month low of $3.21 and a 12 month high of $9.14.
In related news, CEO Ronald Menezes bought 5,800 shares of the stock in a transaction that occurred on Thursday, August 12th. The stock was bought at an average cost of $6.98 per share, for a total transaction of $40,484.00. Following the purchase, the chief executive officer now directly owns 505,800 shares of the company’s stock, valued at $3,530,484. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Oliver Christian Bennett sold 3,615 shares of Sientra stock in a transaction that occurred on Friday, August 20th. The shares were sold at an average price of $6.93, for a total transaction of $25,051.95. Following the sale, the insider now owns 80,483 shares of the company’s stock, valued at $557,747.19. The disclosure for this sale can be found here. Insiders have acquired a total of 8,698 shares of company stock worth $59,002 in the last three months. Insiders own 1.10% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. X Square Capital LLC increased its holdings in shares of Sientra by 0.7% during the 2nd quarter. X Square Capital LLC now owns 291,001 shares of the medical instruments supplier’s stock valued at $2,316,000 after purchasing an additional 1,941 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in shares of Sientra by 8.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 28,344 shares of the medical instruments supplier’s stock valued at $226,000 after purchasing an additional 2,261 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Sientra by 10.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,572 shares of the medical instruments supplier’s stock valued at $267,000 after purchasing an additional 3,093 shares in the last quarter. American International Group Inc. increased its holdings in shares of Sientra by 11.9% during the 1st quarter. American International Group Inc. now owns 30,193 shares of the medical instruments supplier’s stock valued at $220,000 after purchasing an additional 3,214 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in shares of Sientra during the 1st quarter valued at approximately $33,000. Institutional investors and hedge funds own 88.81% of the company’s stock.
Sientra Company Profile
Sientra, Inc operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM.
Featured Story: How to start trading in the forex market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.